The National Academy of Sports Medicine® (NASM), the global leader in fitness and wellness training and certifications, is launching its latest course, "Understanding Weight Loss Medications: A Guide ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...

More and more Americans are turning to GLP-1 injections to lose weight. FOX 7 Austin's Rebecca Thomas spoke to an Austin physician to discuss.

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress.

Shares of Viking Therapeutics have fallen by more than half since the stock peaked early last year. Viking Therapeutics is developing a drug that might be able to outperform today's most popular ...

Eli Lilly broke new ground with Zepbound. It's a dual GLP-1/GIP agonist, meaning it mimics the action of those two hormones. It was the first treatment of its kind to earn the green light from ...